Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

HERZLIYA, Israel, October 10, 2019 – Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses,…

Continue Reading Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

HERZLIYA, Israel, March 27, 2019 – Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses,…

Continue Reading Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board

HERZLIYA, Israel, November 27, 2018 – Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses,…

Continue Reading Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board